12:00 AM
 | 
Feb 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dirucotide: Phase II data

Top-line data from the double-blind, placebo-controlled, European Phase II MINDSET-01 trial in 218 patients with RRMS, showed that IV dirucotide did not meet the primary endpoint of an annualized relapse rate or associated secondary MRI endpoints. The...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >